Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.

Sabine Kürzel; André-René Blaudszun; Lilly Stahl; Regina Herbst; Frank Kroschinsky; Josef Birkmann; Annette Hänel; Kerstin Schaefer-Eckart; Gerhard Ehninger; Friedrich Fiedler; Martin Bornhäuser; Stephan Fricke; Mathias Hänel

doi:10.1007/s00432-021-03702-7

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.

Sabine Kürzel, André-René Blaudszun, Lilly Stahl, Regina Herbst, Frank Kroschinsky, Josef Birkmann (Co-author), Annette Hänel, Kerstin Schaefer-Eckart (Co-author), Gerhard Ehninger, Friedrich Fiedler, Martin Bornhäuser, Stephan Fricke, Mathias Hänel

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	1171-1181
Journal	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume	148
Issue number	5
DOIs	https://doi.org/10.1007/s00432-021-03702-7
Publication status	Published - 2022

Keywords

B-CELL LYMPHOMA
HIGH-DOSE CHEMOTHERAPY
HODGKINS-LYMPHOMA
ELDERLY-PATIENTS
OPEN-LABEL
BRENTUXIMAB VEDOTIN
CHOP CHEMOTHERAPY
PROGNOSTIC SCORE
PLUS RITUXIMAB
TRANSPLANTATION

Access to Document

10.1007/s00432-021-03702-7

Cite this

Kürzel, S., Blaudszun, A.-R., Stahl, L., Herbst, R., Kroschinsky, F., Birkmann, J., Hänel, A., Schaefer-Eckart, K., Ehninger, G., Fiedler, F., Bornhäuser, M., Fricke, S., & Hänel, M. (2022). Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , 148(5), 1171-1181. https://doi.org/10.1007/s00432-021-03702-7

Kürzel, Sabine ; Blaudszun, André-René ; Stahl, Lilly et al. / Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 2022 ; Vol. 148, No. 5. pp. 1171-1181.

@article{bce1672f59ef4c5c84c4bf49cd391f8f,

title = "Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.",

keywords = "B-CELL LYMPHOMA, HIGH-DOSE CHEMOTHERAPY, HODGKINS-LYMPHOMA, ELDERLY-PATIENTS, OPEN-LABEL, BRENTUXIMAB VEDOTIN, CHOP CHEMOTHERAPY, PROGNOSTIC SCORE, PLUS RITUXIMAB, TRANSPLANTATION",

author = "Sabine K{\"u}rzel and Andr{\'e}-Ren{\'e} Blaudszun and Lilly Stahl and Regina Herbst and Frank Kroschinsky and Josef Birkmann and Annette H{\"a}nel and Kerstin Schaefer-Eckart and Gerhard Ehninger and Friedrich Fiedler and Martin Bornh{\"a}user and Stephan Fricke and Mathias H{\"a}nel",

note = "Birkmann; Sch{\"a}fer-Eckart: Klinikum Nuernberg, Paracelsus Medical Private University, Medical Clinic 5, Nuremberg, Germany",

year = "2022",

doi = "10.1007/s00432-021-03702-7",

language = "English",

volume = "148",

pages = "1171--1181",

journal = "JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY ",

issn = "0171-5216",

publisher = "Springer Nature",

number = "5",

}

Kürzel, S, Blaudszun, A-R, Stahl, L, Herbst, R, Kroschinsky, F, Birkmann, J, Hänel, A, Schaefer-Eckart, K, Ehninger, G, Fiedler, F, Bornhäuser, M, Fricke, S & Hänel, M 2022, 'Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.', JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol. 148, no. 5, pp. 1171-1181. https://doi.org/10.1007/s00432-021-03702-7

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. / Kürzel, Sabine; Blaudszun, André-René; Stahl, Lilly et al.
In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , Vol. 148, No. 5, 2022, p. 1171-1181.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.

AU - Kürzel, Sabine

AU - Blaudszun, André-René

AU - Stahl, Lilly

AU - Herbst, Regina

AU - Kroschinsky, Frank

AU - Birkmann, Josef

AU - Hänel, Annette

AU - Schaefer-Eckart, Kerstin

AU - Ehninger, Gerhard

AU - Fiedler, Friedrich

AU - Bornhäuser, Martin

AU - Fricke, Stephan

AU - Hänel, Mathias

N1 - Birkmann; Schäfer-Eckart: Klinikum Nuernberg, Paracelsus Medical Private University, Medical Clinic 5, Nuremberg, Germany

PY - 2022

Y1 - 2022

KW - B-CELL LYMPHOMA

KW - HIGH-DOSE CHEMOTHERAPY

KW - HODGKINS-LYMPHOMA

KW - ELDERLY-PATIENTS

KW - OPEN-LABEL

KW - BRENTUXIMAB VEDOTIN

KW - CHOP CHEMOTHERAPY

KW - PROGNOSTIC SCORE

KW - PLUS RITUXIMAB

KW - TRANSPLANTATION

U2 - 10.1007/s00432-021-03702-7

DO - 10.1007/s00432-021-03702-7

M3 - Original Article

C2 - 34176014

SN - 0171-5216

VL - 148

SP - 1171

EP - 1181

JO - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

JF - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

IS - 5

ER -

Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J et al. Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY . 2022;148(5):1171-1181. doi: 10.1007/s00432-021-03702-7